PDCD1 and neoplasm: The results suggested that the combination blockade of the PD-1/PD-L1- and CTLA-4-negative co-stimulatory pathways allowed tumor-specific T cells that would otherwise be inactivated to continue to expand and carry out effector functions, thereby shifting the tumor microenvironment from suppressive to inflammatory (60).